我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
117
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
FDA
Food and Drug Administration
- GEn1E Lifesciences, a Phase 2 clinical-stage biotech company, has partnered with Rubicon Research to combine AI-powered patient endotyping with manufacturing and commercialization capabilities. - The collaboration will leverage GEn1E's proprietary GRID AI platform to enable precise patient stratification across Rubicon's portfolio, including central nervous system programs. - GEn1E's lead program, a host-directed small-molecule dual-signal modulator, has advanced from discovery to Phase 2 in approximately 2.5 years and received FDA Fast Track designation. - The partnership aims to enhance scalability and capital efficiency while expanding access to targeted therapies for patients with high unmet medical needs.
